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HIV-1In addition to neutralization, antibodies mediate other antiviral activities including antibody-dependent
cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), as well as complement
deposition. While it is established that progressive HIV infection is associated with reduced ADCC and ADCP,
the underlying mechanism for this loss of function is unknown. Here we report considerable changes in FcR
expression over the course of HIV infection on both mDCs and monocytes, including elevated FcγRI
expression in acute HIV infection and reduced expression of FcγRII and FcγRIIIa in chronic HIV infection.
Furthermore, selective blockade of FcγRII alone was associated with a loss in ADCP activity, suggesting that
FcγRII plays a central role in modulating ADCP. Overall, HIV infection is associated with a number of changes
in FcR expression on phagocytic cells that are associated with changes in their ability to respond to antibody-
opsonized targets, potentially contributing to a failure in viral clearance in progressive HIV-1 infection.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
In addition to their ability to neutralize pathogens, antibodies are
able to mediate a number of additional antiviral functions following
ligation of innate immune cells via an Fc receptor (fragment, crys-
tallizable receptor, FcR) (Nimmerjahn and Ravetch, 2008; Oganesyan
et al., 2008). These include stimulation of cytokine production,
induction of cytolytic activity, antibody-mediated cellular-phagocy-
tosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), or
complement mediated cytotoxicity (CMC).
FcRs belong to the immunoglobulin superfamily and bind to the
constant regions of antibodies (Nimmerjahn and Ravetch, 2007). Five
different FcRs, with distinct antibody isotype binding properties, exist
in humans including FcαR (IgA), FcγR (IgG), FcμR (IgM), FcδR (IgD),
and FcεR (IgE). Among the IgG binding FcRs, 3 isoforms of FcγR with
distinct functions have been identiﬁed: the FcγRI (high afﬁnity),
FcγRII (a and c, medium–low afﬁnity), and FcγRIII (a and b, medium–
low afﬁnity) are activating receptors, whereas FcγRIIb delivers
inhibitory signals (Siberil et al., 2007). All cells of the innate immune
system, and a few non-innate immune cells, express FcRs includingmonocytes/macrophages, granulocytes, DC, and mast cells that
express both inhibitory and activating FcγR, natural killer (NK) cells
that express the activating receptor FcγRIIIa, and B cells that only
express the inhibitory receptor FcγRIIb (Anderson, 1989; Nimmer-
jahn and Ravetch, 2008).
Different combinations of FcRs on innate immune cells allow
antibodies to induce a broad range of innate immune responses
depending on the innate immune cell engaged, that may play a vital
role in antiviral or antitumor immune responses. Importantly, ADCC
and ADCP activity have been associated with better outcome in
several diseases such as chronic viral infections (Shore et al., 1974),
autoimmune diseases (Laszlo et al., 1986) and particular cancers
(Dall'Ozzo et al., 2004; Natsume et al., 2009). In addition to NK cells
that mediate potent ADCC via FcγRIIIa, other innate immune cells,
such as monocytes, DCs, and neutrophils, are also able to mediate
ADCC as well as ADCP, and have equally been implicated as critical
responders to antibody-opsonized material. Furthermore, unlike
neutralizing antibodies, ADCC-inducing antibodies have been ob-
served early in HIV infection, and correlate with better disease out-
come (Aasa-Chapman et al., 2005; Forthal et al., 2001). Furthermore,
results from the RV144 Thai trial suggest that additional antiviral
humoral mechanisms, beyond neutralization, may play a critical role
not only after infection butmay also protect individuals from infection
(Rerks-Ngarm et al., 2009).
161A.-S. Dugast et al. / Virology 415 (2011) 160–167While a great deal of work has focused on the role of ADCC activity
in the control of HIV infection, little has been done to understand the
role of other antibody-mediated effector functions, such as ADCP,
which may also play a vital role in the effective clearance of immune
complexes that are abundantly produced during progressive HIV
infection (Tomaras et al., 2008). Thus robust ADCP-inducing anti-
bodies could play a critical role in the rapid clearance of antibody-
opsonized viral particles from the peripheral circulation where
they may contribute to immune activation and disease progression
(Tomaras et al., 2008).
Given the central role of FcRs in regulating the recruitment of
innate immune responses, including ADCP, we speculated that
changes in FcR expression may provide clues regarding the FcRs
that are involved in viral clearance at different stages of HIV infection.
Here we report that acute infection was associated with an increased
expression of FcγRI, whereas chronic infection was associated with a
decreased FcγRII and FcγRIII expression on a variety of myeloid cell
subsets (mDC, pDC and monocytes). Phagocytic activity was signif-
icantly elevated in acute HIV infection while it was reduced in chronic
infection, suggesting that changes in particular FcRs are associated
with defective ADCP-inducing antibody function at different stages of
HIV infection that may contribute to a differential capacity to clear
immune complexes during HIV infection.
Results
Dramatic changes in the frequency and magnitude of FcR expression
starting in acute HIV-1 infection
Chronic HIV infection is associated with an accumulation of
dysfunctional NK cells (Alter et al., 2005; Alter et al., 2004; Eger and
Unutmaz, 2004; Hu et al., 1995; Mavilio et al., 2003), and more recent
work has shown that impaired NK-mediated ADCC activity is related
to reduced expression of FcγRIIIa on the surface of these cytolyticA
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Fig. 1. Acute HIV-1 infection is associated with changes in FcγRI expression on mDCs and m
(CD64) expression on (i) mDCs, (ii) pDCs and (iii) monocytes derived from acute (●), chroneffector cells (Liu et al., 2009). Given the profound impact of reduced
FcγR expression on NK cell mediated ADCC, it is plausible that changes
in FcR expression on other cell subsets over the course of HIV infection
may also modulate their capacity to respond to cytolytic antibodies.
Thus we compared the frequency and magnitude of the expression of
the 3 main Fcγ-receptors (FcγRI, FcγRII, FcγRIIIa) as well as FcεR and
FcαR at different stages of HIV infection on several innate immune cell
subsets, starting in acute HIV infection.
FcγRI is the sole high-afﬁnity receptor for monomeric IgG that is
constitutively expressed onmonocytes, macrophages and neutrophils
(Hulett and Hogarth, 1994; Ravetch and Kinet, 1991), and has been
shown to play a central role in the induction of ADCC and ADCP
(Diamond et al., 1978). HIV infection was associated with signiﬁcant
changes in the frequency of cells expressing FcγRI (Fig. 1A) and in the
mean ﬂuorescence intensity (MFI) of this FcR (Fig. 1B) on innate
immune cells. In acute infection, we observed an increase in the
frequency of FcγRI expressing mDCs (Fig. 1Ai) (pb0.001) and in the
MFI of FcγRI expression on monocytes (Fig. 1Biii) (pb0.001)
compared to chronically infected individuals and healthy controls.
Similar to previous reports suggesting that pDCs do not express FcγRI
(Bave et al., 2003), we did not observe FcγRI expression on pDCs
(Fig. 1Bii). In summary, we found that only acute HIV infection is
associated with a robust increase in the frequency of mDCs expressing
FcγRI and an increased expression of FcγRI on monocytes, potentially
suggesting that these innate immune cells may expand and/or
upregulate the expression of this high-afﬁnity FcγR preferentially at
this early stage of the infection in response to the large burst of viral
replication and/or the early cytokine cascade (Table 1).
In contrast to FcγRI, FcγRII has a low afﬁnity for monomeric IgG
and typically only binds multimerized IgGs found on immune
complexes (Hulett and Hogarth, 1994; Ravetch and Kinet, 1991).
FcγRII+ mDCs (Fig. 2Ai) and FcγRII+ monocytes (Fig. 2Aiii) were
slightly reduced in chronic untreated and chronic treated individuals,
respectively, compared to controllers and negative controls. MoreB
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onocytes. The dot plots depict changes in the frequency (A) and intensity (B) of FcγRI
ic treated (■), chronic untreated (▲), controllers (▼) and HIV-1 negative controls (♦).
Table 1
Patient characteristics.
Groups n Viral load (RNA copies/ml) CD4 T cells (/μl)
HIV-negative controllers 23
Controllers 17 710 819
Acute 17 18,066,300 460
Chronic treated 20 b50 716
Chronic untreated 24 41,562 538
162 A.-S. Dugast et al. / Virology 415 (2011) 160–167interestingly, FcγRII expression was signiﬁcantly reduced on mono-
cytes in both chronic treated and untreated HIV-1 infected patients
compared to controllers (pb0.01 and pb0.05, respectively, Fig. 2Biii).
Similar patterns of FcγRII expression were observed on mDCs
(Fig. 2Bi) and pDCs (Fig. 2Bii), suggesting that despite a reduction in
viral replication with successful antiretroviral therapy, expression of
FcγRs does not return to normal levels, which potentially results in a
persistent reduction in ADCC/ADCP activity. These data suggest that
FcγRII is signiﬁcantly downregulated on the surface of multiple innate
immune cell subsets in both chronic treated and untreated HIV-1
infection, potentially resulting in irreversibly reduced ADCP activity in
progressive infection even in the absence of active viral replication
(Liu et al., 2009).
Like FcγRII, FcγRIIIa also binds antibodies with a weak afﬁnity, and
thus binds multimerized IgG complexes more readily (reviewed by
Nimmerjahn and Ravetch, 2008). Previous work has shown that
FcγRIIIa expression is reduced on the surface of NK cells in chronic HIV
infection, correlating with reduced ADCC activity (Liu et al., 2009).
Interestingly, we also observed reduced FcγRIIIa expression onmDCs in
both acute and chronic untreated HIV-1 infection compared to HIV-1
negative controls (pb0.001, for both comparisons Fig. 3Bi). In addition,
while FcγRIIIa+ monocytes were present at higher frequencies ini mDC
ii pDC
iii Monocytes
A
%
 F
cγ
R
II 
0
20
40
60
80
100
0
20
40
60
80
100
**
0
20
40
60
80
100
*
*
**
Ac
ute
Ch
ron
ic 
tre
ate
d
Ch
ron
ic
 
un
tre
ate
d
Co
ntr
olle
rs
HIV
- 
Fig. 2. FcγRII expression is strongly downregulated in chronic HIV infection. The frequenc
(●), chronic treated (■), chronic untreated (▲), controllers (▼) and HIV-1 negative controcontrollers than in all the other groups (pb0.05 for all comparisons,
Fig. 3Aiii), its expression levels onmonocyteswere downregulated in all
chronically infected individuals independent of treatment or sponta-
neous control compared to acute and HIV-negative controls (pb0.001,
for both comparisons Fig. 3Biii). Thus similar to FcγRII, FcγRIIIa
expression is reduced on mDCs and monocytes in chronic HIV-1
infection, likely contributing to reduced ADCC/ADCP activity, whereas it
is expressed at higher levels on innate immune cells in controllers,
potentially allowing them to clear virus from the circulation more
effectively.
Finally we examined changes in FcαR and FcεR expression, which
bind to IgA and IgE, respectively. While the frequency of mDCs and
pDCs expressing FcαR and FcεR was extremely low, we observed an
enrichment in the frequency of FcαR+monocytes at all stages of HIV-
1 infection (Fig. 4). Acute HIV infection was associated with a trend
towards an increase in the frequency of FcεR+monocytes (Fig. 4Aiii),
elevated FcεR+ pDCs (Fig. 4Aii), and a decreased frequency of FcαR+
monocytes compared to all groups (pb0.001 Fig. 4Ciii). Overall, both
FcεR and FcαR were weakly expressed on innate immune cells;
however, acute HIV infection was associated with a higher frequency
of FcεR+ pDCs and monocytes, suggesting that FcεR expression may
also be upregulated to contribute to clearance of immune complexes
bound by antibodies of other isotypes during early HIV-1 infection.
Impairment of phagocytic activity in untreated chronically HIV-infected
individuals
Previous reports that aimed at studying the underlyingmechanism(s)
accounting for alterations in phagocytic activity in progressive HIV
infection (Kedzierska et al., 2002; Kedzierska et al., 2001) (and reviewed
byKedzierska et al., 2003) have shown that compromisedADCP activity is
associated with a reduction in FcγRIIIa mobilization to the cell surfaceB
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Fig. 3. FcγRIIIa expression is downregulated on mDC and monocytes in chronic HIV-1 infection. The frequency (A) of FcγRIII+ cells and the expression (B) of FcγRIII on mDCs, pDCs
and monocytes were compared in subjects in HIV-infected subjects in acute (●), chronic treated (■), chronic untreated (▲), controllers (▼) and HIV-1 negative controls (♦).
163A.-S. Dugast et al. / Virology 415 (2011) 160–167potentially due to shedding (Webster et al., 2006), or due to reduced
expression of the γ signaling subunit of FcγRIIIa in HIV-infected
phagocytes (Kedzierska et al., 2002; Leeansyah et al., 2007). We did not
observe any correlation between ADCP activity and CD4 counts or viral
loads (datanot shown); thus,we sought to determinewhether changes ini mDC
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iii Monocytes
FcεR
BA
%
 F
cε
R
 
M
FI
 F
cε
R
 
0
10
20
30
40
50
0
10
20
30
40
50 **
0
5
10
15 *
Ac
ute Ch
 tx
Ch
 un
tx
Co
ntr
olle
rs
HIV
- 
0
10000
20000
30000
40000
50000
0
5000
10000
15000
0
10000
20000
30000
40000
50000
Ac
ute Ch
 tx
Ch
 un
tx
Co
ntr
olle
rs
H
Fig. 4. Elevated frequencies of FcεR+monocytes in acute HIV-1 infection. The percentage an
pDCs and monocytes derived from patients at different stages of the infection including cells
HIV-1 negative controls (♦).FcR expression at different stages of HIV infection on mDCs and
monocytesmaybe associatedwithdifferences in their phagocytic activity.
Thuswe employed an opsonized, CFSE-labeled cell line, p815 cells, coated
with p815-speciﬁc antibodies, to determine FcR-mediated phagocytic
activity by the different innate immune effector cells by measuring CFSEFcαR
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d intensity FcεR (CD23) (A and B) and FcαR (CD89) (C and D) were compared on mDCs,
derived from acute (●), chronic treated (■), chronic untreated (▲), controllers (▼) and
164 A.-S. Dugast et al. / Virology 415 (2011) 160–167cell-labeled uptake by ﬂow cytometry in the presence or absence of
antibody coating. Our data demonstrate that mDCs and monocytes from
acutely infected individuals possess an enhanced capacity to mediate
ADCP, as these cellswere able to takeupelevated frequencies of antibody-
coated CFSE+ p815 cells compared to cells from chronically infected
individuals off therapy (pb0.1 and pb0.05 respectively, Fig. 5Ai),
suggesting that elevated FcγRI expression observed on mDCs and
monocytes in acute infection may contribute to an enhanced capacity to
clear immune complexes early in infection. We also observed a reduced
frequency of mDC mediated phagocytosis among untreated chronically
infected patients compared to controllers, chronic treated and uninfected
controls (Fig. 5Ai). This compromised frequency of phagocytic cells was
also observed in monocytes in chronic untreated patients compared to
uninfected controls (pb0.05, Fig. 5Aii). These data suggest that changes in
FcR expression on innate immune cells over the course of HIV-1 infection
modulate ADCP activity.A
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of phagocytic cells that have taken up an antibody-coated target cell (A) or the intensity of p
patients, chronic treated, chronic untreated, controllers and HIV-1 negative individuals. (C) T
(ii) in 3 different donors in the presence of FcγR-blocking antibodies.While the frequency of phagocytic cells provides insights into the
ability of the total population of innate immune cells to mediate
ADCP, we also aimed to determine whether on a per cell level, ADCP
differed among the patient populations. Thus we compared the
intensity of phagocytosis on a per cell level by determining the
difference in themean ﬂuorescence intensity (dMFI) of CFSE+mDCs
or monocytes in the presence of non-coated or antibody-coated
p815 cells. No difference was observed in phagocytosis of the
uncoated p815 cells among the patient populations, demonstrating
that this ADCP activity is speciﬁc to the presence of the antibody.
Moreover, the level of antibody-mediated phagocytosis (dMFI) on a
per cell level was reduced in chronic untreated subjects compared
to the chronically treated individuals in mDCs (Fig. 5Bi) as well as
in monocytes (pb0.05, Fig. 5Bii), suggesting that not only there
are fewer phagocytic innate immune cells, but on a per cell level,
phagocytic cells also mediated ADCP inefﬁciently.ii
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165A.-S. Dugast et al. / Virology 415 (2011) 160–167Given the dramatic changes in FcγR expression in HIV infection
and their associated effect on compromising ADCP, we next sought to
deﬁne whether changes in all or individual FcγRs modulated ADCP
differentially using selective blocking reagents (Fig. 5C). As previously
described in tumor cells (Richards et al., 2008), neither 10 μg/ml of an
irrelevant murine IgG nor FcγRIIIa blocking antibody had an impact
on the capacity of mDCs or monocytes to induce ADCP. However
selective blockade of either FcγRII alone or in combination with
FcγRIIIa decreased ADCP in mDCs (Fig. 5Ci) and to a lesser extent in
monocytes from healthy donors (Fig. 5Cii). Furthermore, the selective
blockade of FcγRI alone also reduced ADCP activity in monocytes,
albeit to a lesser extent than FcγRII. Moreover, triple blockade of
FcγRI, FcγRII, and FcγRIIIA resulted in more robust inhibition of ADCP,
suggesting that FcγRI may also contribute to the induction of
phagocytosis (Fig. 5Cii). Thus overall, our data conﬁrm that FcγRI
and FcγRII expression on phagocytic cells play a central role in
modulating ADCP over the course of HIV-1 infection. These data newly
suggest that changes in FcγR expression over the course of HIV-1
infection, including an increase in FcγRI in acute infection and a
decline in FcγRII expression in chronic infection, may differentially
contribute to changes in ADCP function at these different stages of
disease, altering the capacity of innate immune cells to clear and/or
control HIV infection (Richards et al., 2008).
Discussion
Whereas ADCC has been shown to play a crucial role in better
disease outcome in HIV-1 infection (Aasa-Chapman et al., 2005)
(Forthal et al., 2001), little is known about additional non-neutralizing
antiviral antibody functions, including ADCP whichmay play a central
role in antiviral control through the rapid clearance of immune
complexes. Furthermore, the recent results from the Thai trial suggest
that non-neutralizing antibodies with the capacity to recruit the
innate immune system through FcγR may have contributed to
protection from HIV infection (Rerks-Ngarm et al., 2009); however,
the precise effector mechanism of these non-neutralizing antibodies
is not known. In this study, we show that HIV-1 infection is associated
with signiﬁcant alterations in the frequency of FcγR expressing cells,
and that these changes occur as early as acute HIV-1 infection. In fact,
acute infection was strongly associated with an increase in the
frequency of FcγRI+ mDCs as well as an increase in FcγRI expression
on monocytes. In contrast, as opposed to acute infection, chronic HIV
infection was associated with a signiﬁcant and persistent down-
regulation of FcγRII expression, even following a reduction in viral
replication with antiretroviral therapy. Interestingly, we did not
observe any statistical differences in the FcγRII expression on innate
immune cells between chronics and HIV-negative individuals,
suggesting that additional factors, independent of the receptor
expression, may also contribute to alterations in ADCP activity.
Furthermore, selective blockade of either FcγRI or FcγRII alone or in
combination with FcγRIIIa on monocytes resulted in decreased
phagocytosis, suggesting that alterations in these speciﬁc FcRs may
play a central role in modulating ADCP activity. These data strongly
suggest that increased expression of FcγRI on monocytes in acute
infection may help promote viral clearance of immune complexes,
whereas decreased FcγRII expression in chronically infected in-
dividuals may dampen ADCP, resulting in compromised clearance of
immune complexes in later disease. Overall, these results demon-
strate that HIV-1 infection is associated with changes in the expres-
sion of speciﬁc FcγRs on innate immune cells that are responsible for
alterations in the capacity of these cells to mediate ADCP in chronic
infection, potentially resulting in a failure of innate immune cells to
efﬁciently clear immune complexes and therefore help control viral
replication.
Several lines of evidence suggest that a number of myeloid cell
activities are impaired following HIV-1 infection in vivo as well as invitro including chemotaxis (Tas et al., 1988; Wahl et al., 1989),
phagocytosis (Kedzierska et al., 2002; Kedzierska et al., 2000;
Leeansyah et al., 2007; Webster et al., 2006), intracellular killing
(Biggs et al., 1995), and cytokine production (Kedzierska et al.,
2001). Several groups have speculated that the compromised
phagocytic activity following HIV infection may partially contribute
to the AIDS-associated pathogenesis, as the loss of these functions
could result in poor antibody-mediated recruitment of innate im-
mune cell associated viral control (Crowe, 1995; Crowe and Sonza,
2000; Kedzierska et al., 2003); however, the mechanism by which
this activity is lost is unknown. Previous reports have demonstrated
that HIV-1 infection of monocyte derived macrophages (MDM)
results in a defect in phagocytic activity (Leeansyah et al., 2007) in
the absence of changes in the surface expression of FcγRs in vitro
(Kedzierska et al., 2002). However only a small fraction of mono-
cytes and mDCs are infected in vivo, and alterations in innate
immune cell mediated phagocytic activity extend far beyond this
small subset of infected cells. Thus additional mechanisms must
account for changes in ADCP activity in the larger majority of
phagocytic cells. Here we show that changes in the frequency and
expression levels of particular FcγRs over the course of HIV-1
infection, starting in acute infection, may contribute to variation in
the capacity of these cells to mediate ADCP.
Changes in FcR expression at different stages of HIV infection may
provide critical insights into the receptors that may be centrally
involved in the clearance of antibody-opsonized material. Along these
lines, we observed a unique upregulation of FcγRI on monocytes in
acute HIV infection, suggesting that at this early stage of infection,
FcγRI expression may be critical for early clearance of immune
complexes. Moreover, selective blockade of FcγRI on monocytes
decreased ADCP activity, conﬁrming its role in ADCP mediated
clearance of antibody-opsonized material. In fact, FcγRI is the only
high-afﬁnity FcγR and is able to bind monomeric antibodies (Hulett
and Hogarth, 1994; Ravetch and Kinet, 1991). Upregulation of FcγRI
expressing monocytes may provide these phagocytic cells with the
capacity to respond to antibody-opsonized material with higher
sensitivity, to aide in viral control. Previous studies have shown that
FcγR expression is altered on innate immune cells in other viral
infections, driven by interferon-γ (IFN-γ) (Okayama et al., 2000),
tumor growth factor-β (TGF-β) (Tridandapani et al., 2003) or other
stimuli including LPS, associated with chronic immune activation in
HIV as well as in SIV infection (Arend et al., 1987; Pricop et al., 2001)
(Brenchley et al., 2006), supporting the fact that changes in the
inﬂammatory milieu, due to cytokine cascades following infection,
may drive alterations in FcR expression at different stages of HIV
infection, potentially modulating the capacity of innate immune cells
to respond to antibody-opsonized material (Arend et al., 1987;
Boruchov et al., 2005; Okayama et al., 2000; Tridandapani et al.,
2003). Moreover, we show that FcγRII expression on mDCs and
monocytes was reduced in chronic HIV infection and that alterations
in the expression of this particular receptor contributed centrally to
the reduced ADCP observed in chronic infection. Similarly, previous
reports from the SLE model suggest that FcγRIIa expression also
declines on monocytes in this inﬂammatory disease contributing to
impaired ADCP clearance of immune complexes in the sera of these
patients (Szucs et al., 1994), strongly suggesting that FcγRIIa
expression is required for phagocytic clearance of immune complexes
in autoimmunity as well as during infection.
While a great deal of research has focused on cross talk between
inhibitory and activating FcRs (Holl et al., 2004), little has been done
in the way of understanding how different activating FcRs may
synergize with one another to modulate effector functions. Moreover,
while the selective blockade of FcγRI and/or FcγRII alone or in com-
bination with FcγRIIIa inhibited ADCP activity, the selective blockade
of FcγRIIIa alone did not modify ADCP (Fig. 5Ci and ii). These data
suggest that both FcγRI and II independently promote ADCP activity,
166 A.-S. Dugast et al. / Virology 415 (2011) 160–167but also may synergize to additively mediate more robust ADCP when
co-expressed on the same innate cell.
Finally, although the antibody-opsonized p815 assay does not
directly measure the HIV-speciﬁc capacity of antibodies to trigger
ADCP activity, it offers an indirect measure of the ADCP capacity of
different innate immune cell subsets (Kondo et al., 1981; Caligiuri
et al., 1993; Grazia Cifone et al., 1990). Thus this assay offers an
indirect measure of the potential capacity of innate immune cells to
mediate clearance of antibody-opsonized material during infection,
that can be antibody-opsonized viral particles, HIV-infected cells, or
other antibody-opsonized material. Thus it is also plausible that
reduced ADCP activity in chronic HIV infection may also result in
compromised clearance of other antibody-opsonized material that
may contribute to reduced control/clearance of other opportunistic
pathogens.
In conclusion, we show here that HIV-associated changes in ADCP
activity in progressive infection may be directly related to changes in
FcR expression. We highlight the potential involvement of particular
FcRs in ADCP to help control viral infection at different stages of HIV
infection, FcγRI in acute infection and FcγRII in viral control of
infection. These data provide new insights into the mechanism of
protective FcR-mediated ADCP activity and its loss over the course of
HIV infection that may be critical for efﬁcient antibody-mediated
control that may make important new targets to enhance protection
mediated by HIV-speciﬁc antibodies through vaccination.
Materials and methods
Subjects
A total of 101 subjects were recruited for this study, including 23
healthy HIV-1 negative control subjects; 24 untreated viremic HIV-1-
infected subjects with an average viral load of 41,562 copies HIV-1
mRNA per ml of plasma (range, 1210–229,000 copies per ml) and an
average of CD4 count of 538 cells per mm3 (range, 29–1041 cells per
mm3); 20 HIV-1-infected subjects receiving highly active antiretro-
viral therapy (HAART), with undetectable viral loads (b50 copies) and
an average of CD4 count of 716 cells per mm3 (range, 193–1534 cells
per mm3); 17 controllers recruited from the controllers cohort at the
Ragon Institute (Pereyra et al., 2008) with an average viral load of 710
copies of RNA per ml plasma (range, 49–1662) and an average of CD4
count of 819 cells per mm3 (range, 445–1297 cells per mm3); and 17
acutely HIV-1-infected individuals recruited from our Boston Acute
Infection cohort. Acute samples were in a Fiebig stage IV–V, with an
average viral load of 18,066,300 copies per ml (range, 200,000–
66,000,000 copies) and an average of CD4 count of 460 cells per mm3
(range, 310–517 cells permm3). All samples were cryopreserved prior
to usage. TheMGH institutional review board approved the study, and
each subject gave written informed consent for participation in the
study (Pereyra et al., 2008).
Phenotyping
Peripheral blood mononuclear cells (PBMCs) were obtained after
Ficoll–Hypaque density gradient centrifugation of whole blood. FcR
expression was assessed on three different cell subsets from
cryopreserved PBMCs: mDCs (myeloid dendritic cells), deﬁned as
CD3neg CD14neg CD123neg and CD11cpos; pDCs (plasmacytoid den-
dritic cells), deﬁned as CD3neg CD14neg CD123pos and CD11cneg; and
monocytes, deﬁned as CD3neg and CD14pos. PBMCs were stained with
blue viability dye (Invitrogen), and thenwith CD64-FITC, CD23-biotin,
CD16-APCCy7, CD89-PE, CD3-alexa700, CD123-PECy5, CD14-PB (BD
Biosciences), CD32-APC (Biolegend), CD11c-PECy5.5 (Invitrogen) and
streptavidin Cascade Yellow (Invitrogen). An average of 6.7 × 105
PBMCs events (range, 3 × 105 to 1 × 106 cells) were acquired for eachindividual on a BD LSRII, and data were analyzedwith FlowJo software
(version 8.7.1).
FcγR-mediated phagocytosis
p815 cells (a mouse leukemic cell line) were stained with 0.25 μM
carboxy-ﬂuorescein succinimidyl ester (CFSE; Molecular Probes) and
incubated with a p815-speciﬁc rabbit monoclonal antibody (10 μg/
ml) (Accurate Chemical), previously used widely to measure human
Fc receptor function (Caligiuri et al., 1993; Grazia Cifone et al., 1990;
Kondo et al., 1981). Coated and uncoated p815 cells were then
coculturedwith previously cryopreserved PBMC from 5 recently acute
infected individuals, 10 chronic untreated, 10 chronic treated, 12
controllers and 10 negative controls at an effector:target ratio of 10:1
in 10% fetal calf serum (Sigma), penicillin, glutamine and streptomy-
cin (CellGro). The percentage of effector cells that took up CFSE-
labeled target cells was monitored by ﬂow cytometry using the
following markers: CD3-Alexa 700, CD14-APC, CD123-PECy5 (BD
Biosciences) and CD11c-PECy5.5 (Invitrogen). Then the delta-mean
ﬂuorescence intensity (dMFI) was calculated as the percentage of
effector cells that phagocytosed CFSE-labeled uncoated-target cells
subtracted from the percentage of effector cells that took up CFSE-
positive target cells from antibody-coated p815 cells. A minimum of
300,000 cells were acquired on a BD LSRII, and analysis was then
performed using FlowJo software.
FcγR blockade assay
Blocking antibodies FcγRI (10 μg/ml, clone 10-1; BD Pharmingen),
FcγRII (10 μg/ml, clone AT10; R&D Systems) and/or FcγRIIIa (10 μg/
ml, clone 3G8; BD Pharmingen) were added to PBMCs for 1 h at 37 °C
before the addition of either antibody-coated or non-coated CFSE-
labeled p815 cells for 3h. Phagocytosis was evaluated as the
proportion of mDCs and monocytes that took up ﬂuorescent
antibody-coated p815 cells by ﬂow cytometry using the following
markers: CD3-Alexa 700, CD14-APC, CD123-PECy5 (BD Biosciences)
and CD11c-PECy5.5 (Invitrogen). Cells were acquired on a BD LSRII,
and analysis was then performed using FlowJo software.
Statistics
Statistical analysis was performed using GraphPad Prism. Statistical
comparisons of marker expression levels were made using one-way
ANOVA. P values of pairwise comparisons were adjusted for multiple
comparisons using Tukey's method. Signiﬁcant differences were noted
when pb0.05. (* represents pb0.05; ** represents pb0.001 and ***
represents pb0.0001).
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